| Title： | Clinical Practice Guideline on Antimyelin Oligodendrocyte Glycoprotein Antibody-associated Disorders (MOGAD) in Children |
| Edition： | Original |
| Classification： | Standard guideline |
| Field： | Comprehensive guideline |
| Countries and regions： | China |
| Guidelines users： | Pediatric neurologists and general pediatricians |
| Evidence classification method： | GRADE |
| Development unit： | Peking University First Hospital and Fudan University GRADE Center |
| Registration time: | 2022-04-01 |
| Registration number： | IPGRP-2022CN190 |
| Purpose of the guideline: | At present, there is no uniform standard for the diagnosis and treatment of children with anti-myelin oligodendrocyte glycoprotein antibody-related diseases (MOGAD). This guideline intends to use evidence-based evidence to answer the key questions in the diagnosis and treatment of MOGAD in children in order to provide more standardized principles. |
Latest registration
